TAKARA HOLDINGS (2531) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the nine months ended Q3 of the fiscal year ending March 2026, Takara Holdings secured higher revenue owing to the growth of its overseas food wholesale business, while Operating Income, Ordinary Income, and Net Income all declined due to increased losses at the Takara Bio Group and the recognition of impairment losses. Revenue was ¥2,915.3B (+9.2% year on year), Operating Income was ¥126.3B (-15.3%), Ordinary Income was ¥125.5B (-21.8%), and Net Income attributable to owners of the parent was ¥72.0B (-44.8%). The primary driver of revenue growth was the +20.1% increase in Revenue at the Takara Shuzo International Group, while the main factors behind the decline in earnings were lower margins at that group, increased segment losses at the Takara Bio Group, and the recognition of ¥38.7B in impairment losses.

Factors Affecting Performance

【Revenue】Consolidated Revenue was ¥2,915.3B (+9.2% year on year). By segment, the Takara Shuzo International Group was the largest contributor to revenue growth, with Revenue of ¥1,600.2B (+20.1%), while Other Businesses also contributed with Revenue of ¥109.4B (+7.3%). In contrast, Takara Shuzo, the core business, posted Revenue of ¥933.0B (-2.1%), and the Takara Bio Group posted Revenue of ¥283.9B (-3.0%), indicating that growth remains concentrated in the overseas food wholesale business.

【Profit and Loss】Operating Income was ¥126.3B (-15.3%), and the Operating Income margin declined to 4.3% from 5.6% in the same period of the previous year. The gross margin was 32.3% (32.8% in the previous year), while the SG&A expense ratio was 28.0% (27.2% in the previous year). SG&A expenses increased by +12.4%, outpacing Revenue growth of +9.2%, which was a factor behind the deterioration in margins. By segment, profit at the Takara Shuzo International Group increased by +4.2% to ¥97.6B, but profit growth was sluggish relative to revenue growth, and the margin declined from 7.0% to 6.1%. The Takara Bio Group recorded a segment loss of ¥48.6B, widening from a loss of ¥14.7B in the previous year, and recognized ¥38.7B in impairment losses in this segment. Despite lower Revenue, Takara Shuzo recorded segment profit of ¥58.0B (+8.4%), demonstrating an improvement in its margin. Ordinary Income was ¥125.5B (-21.8%), as interest expenses of ¥11.2B under non-operating expenses increased from ¥4.8B in the previous year, putting pressure on earnings. Net Income was ¥72.0B (-44.8%), as extraordinary income of ¥71.6B, including a ¥64.1B gain on the sale of investment securities, was offset by extraordinary losses of ¥41.5B, including impairment losses; the high effective tax rate of 53.7% also had an impact. Overall, the company experienced higher revenue but lower earnings, with deterioration in the profitability of the domestic core businesses and the Bio business offsetting revenue growth in overseas operations.

Segment Analysis

The Takara Shuzo International Group recorded Revenue of ¥1,600.2B (+20.1%), segment profit of ¥97.6B (+4.2%), and a margin of 6.1% (7.0% in the previous year), indicating slower profit conversion from revenue growth. Takara Shuzo recorded Revenue of ¥933.0B (-2.1%), but segment profit increased by +8.4% to ¥58.0B, and its margin was 6.3%, indicating an improving profitability trend in the domestic business. The Takara Bio Group recorded Revenue of ¥283.9B (-3.0%) and a segment loss of ¥48.6B (loss of ¥14.7B in the previous year), with the deficit widening; the segment also recognized ¥38.7B in impairment losses. Demand trends in the research reagent business and the integration results of the acquisition of Curio Bioscience (¥62.7B in goodwill recognized) will be key to future earnings recovery.

Key Financial Indicators

【Profitability】The Operating Income margin was 4.3%, down from 5.6% in the same period of the previous year, while the Net Income margin also showed a declining trend from 3.6% (on an attributable-to-owners-of-the-parent basis). Annualized ROE remained low at 3.2%; the decline in the gross margin to 32.3% and the increase in the SG&A expense ratio to 28.0% were the primary factors behind the deterioration in profitability.【Cash Quality】Cash and deposits were ¥609.5B, down 26.8% year on year, reflecting cash outflows from M&A, investments, and shareholder returns. Accounts receivable were ¥860.3B and inventories were ¥780.2B, both of which increased, indicating that working capital expanded faster than Revenue growth.【Investment Efficiency】Intangible assets increased to ¥578.4B (+38.8%), while goodwill increased to ¥299.1B (+15.1%), reflecting continued asset growth associated with M&A. Goodwill remains limited to 10.1% of net assets, suggesting that concentration risk related to impairment is limited; however, continued monitoring is necessary in light of the impairment recognized in the Takara Bio business.【Financial Soundness】The Equity Ratio remained high at 59.7%. While long-term borrowings increased to ¥404.7B (+31.9%), short-term borrowings decreased to ¥63.6B (-48.4%), indicating progress toward extending the maturity of funding.

Cash Flow Analysis

Although the cash flow statement is not directly disclosed, an analysis of cash movements based on changes in the balance sheet indicates that cash and deposits decreased by ¥223.6B (26.8%) year on year to ¥609.5B. Accounts receivable increased by +17.3% to ¥860.3B, and inventories increased by +7.2% to ¥780.2B. Working capital expanded at a pace exceeding the 9.2% Revenue growth rate, and the resulting increase in funds tied up in working capital is considered one factor behind the decline in cash. Accounts payable increased by +14.1% to ¥274.5B, but this was insufficient to offset the increases in accounts receivable and inventories. Long-term borrowings increased by +31.9% to ¥404.7B, while short-term borrowings decreased by -48.4% to ¥63.6B, indicating that the funding structure is shifting from short term to long term. The increase in intangible assets and goodwill is considered the counterpart of cash expenditures for investment activities, including the acquisition of Curio Bioscience. The company appears to have experienced a year in which investments, borrowings, and increased working capital combined to compress cash on hand.

Earnings Quality

Net Income attributable to owners of the parent of ¥72.0B was significantly affected by temporary factors, including extraordinary income of ¥71.6B, of which ¥64.1B was a gain on the sale of investment securities, and extraordinary losses of ¥41.5B, of which ¥38.7B was an impairment loss at the Takara Bio Group. The increase from Ordinary Income of ¥125.5B to Profit Before Tax of ¥155.6B was attributable to net extraordinary gains and losses of ¥30.1B. Accordingly, the underlying earnings profile appears weaker when Net Income is assessed based solely on recurring earnings power. Among non-operating income, dividend income of ¥9.0B was a major item, while interest expenses under non-operating expenses increased to ¥11.2B from ¥4.8B in the previous year, reflecting the increase in interest-bearing liabilities. The effective tax rate was high at 53.7%, restricting the conversion of Profit Before Tax into Net Income, while the loss attributable to non-controlling interests of ¥33.6B increased profit attributable to owners of the parent. Comprehensive income was ¥58.9B, below Net Income of ¥72.0B, primarily due to a negative foreign currency translation adjustment of ¥35.8B. The gap between Net Income and comprehensive income indicates that foreign exchange effects on overseas subsidiaries remain a source of earnings volatility not reflected in the income statement.

Earnings Forecast and Guidance

The cumulative Q3 progress rates against the full-year company forecasts of Revenue of ¥3,920.0B, Operating Income of ¥162.0B, and Ordinary Income of ¥157.0B were 74.4%, 78.0%, and 80.0%, respectively, broadly in line with the standard progress level of approximately 75%. Meanwhile, progress toward the full-year forecast of ¥111.0B in profit attributable to owners of the parent was 95.1%, substantially ahead of schedule; however, this was attributable to the accumulated contribution of temporary gains, primarily gains on the sale of investment securities, and differs in nature from an upside in recurring earnings power. No revisions were made to the earnings forecast or dividend forecast during the quarter, and the full-year forecasts remain unchanged. The levels required in Q4 are approximately ¥1,004.7B in Revenue and ¥35.7B in Operating Income. Reduction of losses at the Takara Bio Group and margin improvement in overseas operations will be the key factors determining whether the forecasts are achieved.

Shareholder Returns

The year-end dividend forecast for the fiscal year ending March 2026 is a total of ¥31, consisting of an ordinary dividend of ¥29 and a ¥2 commemorative dividend marking the company’s 100th anniversary. This is expected to remain unchanged from the previous year’s dividend of ¥31. Based on forecast full-year EPS of ¥57.43, the Payout Ratio is 54.0% based on the ¥31 dividend and 50.5% based on the ordinary dividend of ¥29 excluding the commemorative dividend. No revisions were made to the dividend forecast during the quarter, and the policy remains unchanged. Treasury stock increased to ¥51.0B; the Total Return Ratio, including share repurchases in addition to dividends, has not been calculated based on the disclosed information.

Risk Factors

1. Deterioration in the Takara Bio Group’s earnings: Revenue was ¥283.9B, down -3.0% year on year, while the segment loss widened to ¥48.6B from ¥14.7B in the previous year, and ¥38.7B in impairment losses was recognized. Demand trends in the research reagent business and progress in integrating Curio Bioscience will be key to reducing losses going forward.

2. Declining margins in overseas operations: Revenue at the Takara Shuzo International Group increased by +20.1%, while segment profit increased by only +4.2%, resulting in a decline in the margin from 7.0% to 6.1%. The ability to absorb fluctuations in raw material, logistics, labor, and foreign exchange costs remains a challenge.

3. Working capital expansion and declining cash: Accounts receivable increased by +17.3% year on year and inventories increased by +7.2%, both outpacing Revenue growth, while cash and deposits decreased by -26.8% year on year to ¥609.5B. Trends in capital efficiency warrant close monitoring.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Both the Operating Income margin and Net Income margin are below the industry median, indicating that profitability is relatively low within the industry.

Growth and Capital Efficiency

The Revenue growth rate is significantly above the industry median, demonstrating top-tier growth within the industry driven by the expansion of overseas operations.

※Source: Compiled by the Company

Key Points of the Results

1. While the 9.2% Revenue growth rate significantly exceeds the industry median of 3.4%, the Operating Income margin of 4.3% is below the industry median of 5.0%. The fact that scale expansion has not been accompanied by profitability improvement is a key point in the results.

2. The full-year progress rates of 74.4% for Revenue and 78.0% for Operating Income are broadly on track, but the 95.1% progress rate for profit attributable to owners of the parent was significantly supported by temporary factors such as gains on the sale of investment securities, resulting in a gap from the 80.0% progress rate for Ordinary Income.

3. The ¥38.7B impairment loss at the Takara Bio Group and the widening segment loss, together with the ¥62.7B in goodwill recognized in connection with the acquisition of Curio Bioscience, make the progress of integration benefits and monetization key areas to monitor going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,288–¥1,361 at a ±1% change in the cost of equity, and ¥1,317–¥1,328 at a ±0.1 change in ω.

Notes:

• Because progress of Net Income against the full-year forecast (95%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies ahead of schedule tend to exceed their forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated at a somewhat high level.

(Calculation model: Residual Income Model (Ohlson-type, explicit five-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an automatically generated earnings analysis document created by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and, where necessary, after consulting with a professional advisor.

---End of Report---